Bio Business, Los
Angeles, USA
Business Opportunities in Pharmaceuticals and Biotechnology Worldwide
We are the corporate adviser for pharmaceutical and biotechnology companies. We develop the appropriate capital raising, merger and acquisition growth strategies for them. We help them to commercialize their products and services by providing technical, scientific, marketing, financing and management expertise. We direct scientists, physicians and other professionals at R&D organizations and hospitals to offer drug discovery, development and clinical trial services. We are offering the following opportunities for your participation.
Mergers and Acquisitions
Available for Sale:
There are pharmaceutical companies for sale 7 in Argentina, 6 in Brazil, 3 each in Mexico & India, and 1 each in China, Italy, Spain & USA, from $6 to 65 million.
1. USA: A leading niche DEA licensed pharmaceutical grade manufacturing facility to produce OTC or prescription products within the Midwest. The cGMP capabilities can produce a variety of products and currently they specialize in creams, liquids, ointments and gels, semi-solid and solid dose, capsules, powders, and low-end tablets. It generates sales of over $10M with a $7.4M contribution margin.
2. Italy: A leading MNC selling it's worldwide pharmaceutical plant producing pharmaceuticals, veterinary and cosmetics (liquid and solid), marketing branded and generic products that are licensed to export in 50 countries. Sale price is €40M.
3. Spain: Available for sale a fast growing mid-size pharma company with a strong presence in the Spanish market, committed to the commercialization of innovative licensed-in products and own developed products in CNS, Pain, and Respiratory focusing on neuro/psychiatrists, ORLs, rheuma/traumatologists & GPs. It has an international team of 100 employees and a turnover of €23 million with a double digit growth.
4. India: A new APIs manufacturing facility with EU and US standard with an investment of $10M is interested to tie-up and have JV with a MNC.
5. India: The formulations plant has a turnover of $1.2M capable of manufacturing products up to $8-10M without additional investment. Plant is Indian GMP certified and WHO GMP is under renewal. For sale for $3M, also open for joint venture.
6. India: A mid-size manufacturer of solid dosage form APIs, drug pellets & intermediates. Products are exported to Europe, Latin America, SE Asia, Middle East and CIS countries. Sales turnover of $8.5M.
7. China: A GMP-approved plant specialized in solid dosage (hard capsules and tablets) manufacturing, own national sales network with sales and marketing teams in strategic cities. Annual turnover is RMB100M (about $15M) and profit RMB20M (about $3M). Products are OTC and prescription drugs, including cholesterol lowering, cardiovascular, anti-cancer and anti-arthritis drugs. Welcome various forms of buy-outs.
8. Brazil: We offer six pharmaceutical companies for sale in Brazil, one of the fastest growing countries in the world and the leading market in Latin America. Price $6 to 65M plus debt assumption. Direct buyers contact us.
9. Argentina: Buy 50% of a leading generic pharmaceutical manufacturing and marketing company. It has $14M sales, 70% gross margin, 25% EBITDA, $3M working capital and no debt. Sale price is $12M (100% valuation is less than 2 years sales and equivalent to 8 times EBITDA).
10. Argentina: Majority (70-100%) of this
company is on sale. It's in repackaging, analyzing and selling of branded generics products manufactured by third parties, for nervous system, joints, osteopathy, digestive line, reconstitution line and flebology line. 2010 sale is $5.5M and EBITDA is of 17%. The company has a professional team that will stay after the sale.
11. Argentina: A leading generic brand
company is available on sale. It has 175 approved products of which
107 are manufactured and sold at present, and 68 have not been launched yet. It
has $22M sales and $1.4M working capital. The asking price for this company is
for 2.5 years sales, at $55M.
12. Mexico: A local company, part of a global pharma company, with audited sales of $25-40M range and 13% growth rate in past 3 years. Mainly Rx products (which account for over 90% of total sales). Major therapeutic areas are digestive system, hormones and derma products. Staff of about 130 people, and has a local recently renovated factory.
13. Mexico: The pharma company with state-of-the-art facility, brand new plants and machinery, is the biggest specialty manufacturing facility in Latin America. It prides for highly qualified workforce to manufacture creams, tablets, drops, injectables and parenteral drugs. Have Mexican license to manufacture pharmaceutical, hormone and corticosteroid products. It has 36 hormonal products in the pipeline and 8 products at registration stage, the rest are in earlier phases of R&D. Currently the plant is operating at less than 5% capacity, and 17 acres of land is available for future expansion. $50M are invested in this company so far.
Seeking to Buy:
Several major pharma companies are looking for acquisition. We are working on the following opportunities for targets up to $100M.
1. A major pharma company is looking to buy a large API manufacturing facility in Brazil.
2. A MNC is looking for pharma targets for acquisitions in the Andean region (Peru and Ecuador mainly).
3. Another MNC has particularly interest in acquiring bio- companies with neuroscience or gastrointestinal products in Latin America.
4. A fast growing Indian bio-medicine company is looking for manufacturing facility for API and intermediates in India (acquire) or Mexico (JV).
5. A world class probiotic manufacturing company is on the lookout for M&A of a mid-sized (price about $3M) pahrma/biotech company in India.
6. A major pharma company seeking company in the field of respiratory, oncology, dermatology and pain products with sale up to $30M in Brazil.
7. A major healthcare company is interested in acquiring a company in speciality care, hospital care, critical care or injectable facility anywhere around the world.
8. A major healthcare company is looking to acquire an FDA-approved API manufacturing facility or generics (API + dosage form) company in China or South America.
9. A NYSE pharma company is looking to acquire an approved API facility in India. It also seek a solid-oral/liquid facility in the US east coast with DEA licenses and approved ANDAs.
10. A major pharma company wants to buy in Mexico a pharma formulation manufacturing facility with annual sales turnover above $50M, and presence in the private prescription market.
11. An Asian company is looking for an M&A target for a small generic pharma manufacturing and/or distribution company for prescription drugs in US with the annual sales of $10 - $30M.
12. Two buyers are looking for companies in Mexico with Rx portfolio on private market and sales force. Seeking to buy commercial operations with a supply agreement for the manufacturing site.
13. A MNC Pharmaceutical and Clinical research company is looking to buy formulations unit in Mexico with good number of product approvals and ANDA filings, for their Latin American division.
14. An European pharma company wants to acquire a branded prescription product company in the fields of respiratory, allergy, woman health, CNS, pediatric and GI in México, Colombia, Venezuela, Chili or Peru.
15. A major MNC is interested in acquiring a pharma company/products to expand operations in the urology, gastroenterology, female healthcare and endocrinology therapeutic areas in Brazil, Mexico, Argentina and Andean Region (Colombia/Peru).
16. A US biotech company looking to acquire commercial stage companies with branded pharma/biotech products, revenues up to $30M, in Latin America (Argentina preferred, potentially Brazil) and/or SE Asia. JV might also be an option.
17. An European major pharma company is looking for a target with focus on specialty products, in any of the major markets, which could be sold to cardiologists, pneumologists and rheumatologists. Would also consider a company with other specialty prescribed products.
18. A major Asian pharma company looking for opportunities for Rx products, including branded generics, focusing in urology, transplantation, immunology, dermatology, gynecology, hospital anti-infectives and in general hospital products, in Brazil, Argentina and Mexico.
19. A NASDAQ-listed European pharma company is looking for specialty pharma assets or companies offering generic (Rx, OTC, self-care) opportunities mainly in the Northern, Eastern Europe and Russia/CIS. Interested in niche hospital product acquisitions in the South Europe.
20. A respected Chinese API manufacturer is looking for a profitable and growing firm in US to acquire or invest. Targeted turnover $30-60M, about 500 people, strong R&D for finished dose formulation, with oral solid dose cGMP manufacturing facilities. Minimum of 20 of its products must be selling in US with a strong product pipeline. Focus should be on one or more of the oncology, CNS, cardiovascular and respiratory areas.
21. An expanding major Asian/European company is looking for acquisition in Indonesia, Turkey, MENA (like Eqypt) and Latam. Small to mid sized (EUR 30-50M sales) actionable companies as well as product portfolios.
22. An expanding major Asian/European company is looking for majority stake in a listed or private company in India. Size: EUR 30–50M net sales and potential transaction value EUR 100–200M with therapeutic area focus and the dominant anti-infective, gastro, respiratory and pain management. API manufacturing and exports are not required.
23. A premier integrated pharma company in India is looking for a take over of a pharma company which is into manufacturing and marketing with its own brands (OTC, BRANDED GENERICS or GENERICS) in US or any other advanced markets.
Veterinary Medicine
Argentina: Buy the largest veterinary medicines distributor in Argentina distributing products from the largest international and domestic manufacturers. They handle more than 3.000 products holding more than 10% market share. Their sales are 80% for large animals (cattle, horses, hogs, poultry) and 20% for pets.
Biotechnology
and Healthcare
Review the
current investment and partnership opportunities.
1. USA: http://thebestpick.tripod.com/NanoDiagnostics.pdf
2. USA: http://thebestpick.tripod.com/GlycoRegImmune.pdf
3. China: http://thebestpick.tripod.com/RegMedShanghai.html
Drug
Development
We help in therapeutic drug discovery, development, formulation and commercialization. We create market for devices, generic medicines, bulk drugs, APIs and formulations around the world.
API Marketing, Formulation Technologies, and Generic Sourcing
Need reliable source for Orlistat API (500 kg per year) and Celecoxib API (200 kg per month). Looking to acquire a facility to manufacture propofol for regulated markets. Our partner offer controlled release formulations, pellets (ready to fill in capsule) and effervescent tablets. Diverse European product registrations are available for sale. They include Quetiapine, Anastrazole and Letrozole dossiers in numerous pack sizes. We are sourcing the US or European supplier of cabergolina final dosage form for UK and Mexico retail markets.
Hospital
India: Expansion project of the leading regional hospitals in UP, that demonstrated strong top line growth and sustained profitability. 2010 Revenue was Rs 25 crores and CAGR of 16.9% from FY 05 to FY 10. Need to raise $10M, looking for equity investors, sub-debt or quasi-equity. Offer an annual 7-8% coupon with a definite all in return of 15%. Can structure this as a CCD/CCPS.
Clinical Trials
We offer comprehensive suite of clinical services to meet our client's needs. Our affiliated CROs operate state-of-the-art facilities to offer full clinical trial services to pharmaceutical, biotechnology and device companies. We manage the desired outcome through expeditious execution in a sustained and globally acceptable manner. We assist to bring clinical studies to successful completion quickly and cost effectively.
We will be happy
to provide details on any of these opportunities.
We specialize in M&A, investment banking and investment deals in USA, Europe, Latin America, China and India. Please review other opportunities at http://TheNetBusiness.us
Contact us at admin@BioBusinessInc.com with any question, comment and help.
